Highlight
Lenvatinib plus pembrolizumab achieved a 5-month progression-free survival rate of 88.4% in pretreated metastatic B3 thymoma and thymic carcinoma, surpassing historical controls. Treatment demonstrated a manageable safety profile, with hypothyroidism and fatigue the most frequent adverse events. Immune-related toxicities, although observed in some patients, were generally controllable, and no treatment-related deaths occurred.
